Solid Biosciences shareholders approve charter amendment to double authorized common shares to 480 million

• Solid Biosciences held its annual shareholder meeting on June 10, 2026.
• Shareholders endorsed a charter amendment to raise authorized common shares to 480,000,000 from 240,000,000; the amendment was filed on June 10, 2026.
• Investors ratified Ilan Ganot’s appointment, on an advisory basis, as a Class I director through the 2028 annual meeting.
• Shareholders ratified PricewaterhouseCoopers as independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solid Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-265804), on June 10, 2026, and is solely responsible for the information contained therein.